Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 21,216 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 2 Interventional Results available

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

NCT00422799
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 31, 2026, 11:07 AM EDT
Withdrawn Not applicable Interventional

Effects of a Remote Patient Monitoring Protocol on Glycemic Control in Adolescents With Type 1 Diabetes

NCT03466398
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Vivify Health RPM Protocol
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

NCT00153621
View directory record Official record
Conditions
Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional

Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program

NCT00223314
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions
HIV, STD, Pregnancy Prevention Curriculum
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Not applicable Interventional

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

NCT00001111
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study

NCT00271934
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Immune ablation and hematopoietic stem cell support.
Biological
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects

NCT01171664
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, STAHIST
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
South Bend, Indiana • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 31, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664
View directory record Official record
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493
View directory record Official record
Conditions
Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer
Interventions
Venetoclax, Ibrutinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 31, 2026, 11:07 AM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 31, 2026, 11:07 AM EDT
Active, not recruiting Phase 1 Interventional

Safe Accelerated Venetoclax Escalation in CLL

NCT04843904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Obinutuzumab, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BLYS and IFN in SLE

NCT00611611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
fluzone, pneumovax
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195234
View directory record Official record
Conditions
HIV Infections
Interventions
HIV CTL MEP 1000 micrograms, 19 months per subject
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Sacramento, California • Denver, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

NCT00075621
View directory record Official record
Conditions
Multiple Myeloma
Interventions
filgrastim, melphalan, autologous peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Cyclophosphamide for Steroid Refractory GVHD

NCT00492921
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 31, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine

NCT01288014
View directory record Official record
Conditions
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions
Imexon
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 31, 2026, 11:07 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Mixed Tree Nut Food Challenges

NCT02070263
View directory record Official record
Conditions
Food Allergy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Eltrombopag for Moderate Aplastic Anemia

NCT01328587
View directory record Official record
Conditions
Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

NCT01753193
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Anifrolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 68 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Palma, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 31, 2026, 11:07 AM EDT